Artificial Intelligence in Drug Discovery Market by Process, Use Case, Therapy, Tool (ML:DL ), End User & Region - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS AND REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
    • 2.1.2.5 Breakdown of primaries
• 2.2 RESEARCH DESIGN
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.3.2 BOTTOM-UP APPROACH: END-USER ADOPTION
    • 2.3.2.1 Top-down assessment of parent market
    • 2.3.2.2 Company presentations and primary interviews
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET SIZING ASSUMPTIONS
  • 2.5.2 RESEARCH ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW
• 4.2 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER AND COUNTRY (2023)
• 4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL MIX
• 4.5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing number of cross-industry collaborations and partnerships
    • 5.2.1.2 Rising need to reduce time and cost of drug discovery and development
    • 5.2.1.3 Patent expiry of drugs and need for effective new leads
    • 5.2.1.4 Growing utilization of AI to predict drug-target interactions for cancer therapy
    • 5.2.1.5 Integration of AI-assisted multiomics in drug discovery
    • 5.2.1.6 Growing focus on rare disease treatments for orphan drug development
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Leveraging AI for accelerated biotech drug discovery
    • 5.2.3.2 Increased focus on drug discovery in emerging economies
    • 5.2.3.3 Focus on developing human-aware AI systems
    • 5.2.3.4 Growing use of AI in single-cell analysis
    • 5.2.3.5 Easy identification of biomarker and disease subtypes from single-cell data
    • 5.2.3.6 High demand for precision and personalized medicines
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited availability of quality data sets
    • 5.2.4.2 Lack of advanced AI tools and training data sets
    • 5.2.4.3 Computational constraints of advanced AI models
    • 5.2.4.4 Lack of high-quality data sets for model training
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN DRUG DISCOVERY
  • 5.4.2 COMPUTER-AIDED DRUG DESIGN AND ARTIFICIAL INTELLIGENCE
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Dry lab services
    • 5.7.1.2 Wet lab services
      • 5.7.1.2.1 Chemistry software and services
      • 5.7.1.2.2 Biology software and services
        • 5.7.1.2.2.1 Single-cell analysis
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 High-performance computing
    • 5.7.2.2 Next-generation sequencing
    • 5.7.2.3 Real-world evidence/Real-world data
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Cloud computing
    • 5.7.3.2 Blockchain technologies
    • 5.7.3.3 Internet of things
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY FRAMEWORK
• 5.9 PRICING ANALYSIS
  • 5.9.1 INDICATIVE SELLING PRICE FOR DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION
  • 5.9.2 INDICATIVE PRICING ANALYSIS, BY PROCESS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF BUYERS
  • 5.10.3 THREAT OF SUBSTITUTES
  • 5.10.4 THREAT OF NEW ENTRANTS
  • 5.10.5 BARGAINING POWER OF SUPPLIERS
• 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 KEY BUYING CRITERIA
• 5.12 PATENT ANALYSIS
  • 5.12.1 PATENT PUBLICATION TRENDS
  • 5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
  • 5.12.3 MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
• 5.13 UNMET NEEDS AND KEY PAIN POINTS
  • 5.13.1 UNMET NEEDS
  • 5.13.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY
  • 5.13.3 END-USER EXPECTATIONS
• 5.14 KEY CONFERENCES & EVENTS, 2024-2025
• 5.15 CASE STUDY ANALYSIS
• 5.16 BUSINESS MODEL ANALYSIS
• 5.17 INVESTMENT AND FUNDING SCENARIO
• 5.18 IMPACT OF AI/GENERATIVE AI ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
  • 5.18.1 TOP USE CASES AND MARKET POTENTIAL
    • 5.18.1.1 Key use cases
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case study 1: Accelerated drug discovery with generative AI and streamlined workflows
    • 5.18.2.2 Case study 2: Accelerating small-molecule drug discovery with generative AI
  • 5.18.3 IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 AI in drug discovery market
    • 5.18.3.2 Genomics and bioinformatics market
    • 5.18.3.3 Life science analytics market
  • 5.18.4 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biotechnology companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical Companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biotechnology companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS

6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS

• 6.1 INTRODUCTION
• 6.2 TARGET IDENTIFICATION & SELECTION
  • 6.2.1 INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH
• 6.3 TARGET VALIDATION
  • 6.3.1 RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH
• 6.4 HIT IDENTIFICATION & PRIORITIZATION
  • 6.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
• 6.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
  • 6.5.1 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY
• 6.6 LEAD OPTIMIZATION
  • 6.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH
• 6.7 CANDIDATE SELECTION & VALIDATION
  • 6.7.1 HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE

• 7.1 INTRODUCTION
• 7.2 UNDERSTANDING DISEASES
  • 7.2.1 INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY
• 7.3 DRUG REPURPOSING
  • 7.3.1 INCREASING NEED FOR COST-EFFECTIVE TREATMENTS AND RISING AVAILABILITY OF BIOMEDICAL DATA TO AID MARKET GROWTH
• 7.4 DE NOVO DRUG DESIGN
  • 7.4.1 SMALL-MOLECULE DESIGN
    • 7.4.1.1 Increasing use of virtual screening and simulation techniques to drive growth
  • 7.4.2 VACCINE DESIGN
    • 7.4.2.1 Availability of well-validated AI tools to boost market growth
  • 7.4.3 ANTIBODY & OTHER BIOLOGICS DESIGN
    • 7.4.3.1 Advancements in protein modeling to propel segment growth
• 7.5 DRUG OPTIMIZATION
  • 7.5.1 SMALL-MOLECULE OPTIMIZATION
    • 7.5.1.1 Leveraging generative models for identifying potential modifications in molecular structures to aid market growth
  • 7.5.2 VACCINE OPTIMIZATION
    • 7.5.2.1 Effectively predicting vaccine formulations and adjusting delivery vectors to drive growth
  • 7.5.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
    • 7.5.3.1 Increasing adoption of machine learning for predicting protein structures to augment segment growth
• 7.6 SAFETY & TOXICITY
  • 7.6.1 FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO PROPEL MARKET GROWTH
• 8.3 INFECTIOUS DISEASES
  • 8.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
• 8.4 NEUROLOGY
  • 8.4.1 COMPLEX DISEASE DIAGNOSIS AND TREATMENT TO INCREASE ADOPTION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
• 8.5 METABOLIC DISEASES
  • 8.5.1 ROLE OF ARTIFICIAL INTELLIGENCE IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION
• 8.6 CARDIOVASCULAR DISEASES
  • 8.6.1 SEDENTARY LIFESTYLES AND HIGH PREVALENCE OF OBESITY TO INCREASE NOVEL DRUG DEVELOPMENT FOR CARDIAC DISEASES
• 8.7 IMMUNOLOGY
  • 8.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
• 8.8 MENTAL HEALTH DISORDERS
  • 8.8.1 INCREASED OCCURRENCE OF MENTAL HEALTH DISEASES IN DEVELOPED ECONOMIES TO SPUR MARKET GROWTH
• 8.9 OTHER THERAPEUTIC AREAS

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE

• 9.1 INTRODUCTION
• 9.2 END-TO-END SOLUTION PROVIDERS
  • 9.2.1 END-TO-END SOLUTION PROVIDERS TO REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS
• 9.3 NICHE/POINT SOLUTION PROVIDERS
  • 9.3.1 ACCURATE, COST-EFFECTIVE, AND LESS TIME CONSUMPTION TO PROPEL MARKET GROWTH
• 9.4 AI TECHNOLOGY PROVIDERS
  • 9.4.1 SPECIALIZED AI CAPABILITIES WITH FULL-SERVICE MANAGEMENT TO SUPPORT MARKET GROWTH
• 9.5 BUSINESS PROCESS SERVICE PROVIDERS
  • 9.5.1 BETTER ACCESSIBILITY OF HIGH-QUALITY TOOLS AND LOWER DRUG DEVELOPMENT COSTS TO AID MARKET GROWTH

10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL

• 10.1 INTRODUCTION
• 10.2 MACHINE LEARNING
  • 10.2.1 DEEP LEARNING
    • 10.2.1.1 Reduced number of errors and consistent management of data to augment market growth
    • 10.2.1.2 Convolutional neural networks
    • 10.2.1.3 Recurrent neural networks
    • 10.2.1.4 Generative adversarial networks
    • 10.2.1.5 Graph neural networks
    • 10.2.1.6 Other deep learning technologies
  • 10.2.2 SUPERVISED LEARNING
    • 10.2.2.1 Supervised learning to predict drug repositioning and manage high-dimensional datasets
  • 10.2.3 REINFORCEMENT LEARNING
    • 10.2.3.1 Need to accelerate new molecules and maximize performance to augment segment growth
  • 10.2.4 UNSUPERVISED LEARNING
    • 10.2.4.1 Unsupervised learning to perform complex tasks, uncover potential drug candidates, and optimize lead compounds
  • 10.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
• 10.3 NATURAL LANGUAGE PROCESSING
  • 10.3.1 NATURAL LANGUAGE PROCESSING TO IDENTIFY INFORMATION WITHIN UNSTRUCTURED DATA AND ACCELERATE DRUG DISCOVERY
• 10.4 CONTEXT-AWARE PROCESSING & COMPUTING
  • 10.4.1 CONTEXT-AWARE COMPUTING TO IMPROVE PREDICTIONS OF PATIENT-SPECIFIC DRUG RESPONSES AND OPTIMIZE THERAPEUTIC INTERVENTIONS
• 10.5 COMPUTER VISION
  • 10.5.1 COMPUTER VISION TO ENHANCE DRUG DISCOVERY THROUGH ADVANCED IMAGE PROCESSING
• 10.6 IMAGE ANALYSIS
  • 10.6.1 BETTER DRUG DISCOVERY THROUGH IMAGE PROCESSING TECHNIQUES TO SUPPORT MARKET GROWTH

11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT

• 11.1 INTRODUCTION
• 11.2 ON-PREMISES DEPLOYMENT
  • 11.2.1 PROVISION OF MULTI-VENDOR ARCHITECTURE AND SECURITY BENEFITS TO DRIVE MARKET
• 11.3 CLOUD-BASED DEPLOYMENT
  • 11.3.1 FOCUS ON RESEARCH COLLABORATIONS AND ELIMINATION OF SOFTWARE AND HARDWARE PURCHASING COSTS TO DRIVE MARKET
• 11.4 SAAS-BASED DEPLOYMENT
  • 11.4.1 LOWER COSTS, BETTER SECURITY, AND EASIER ACCESS TO AUGMENT MARKET GROWTH

12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 RISING DEMAND FOR COST-EFFECTIVE DRUG DEVELOPMENT TO PROPEL MARKET GROWTH
• 12.3 CONTRACT RESEARCH ORGANIZATIONS
  • 12.3.1 RISING NEED FOR OUTSOURCING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES TO AID MARKET GROWTH
• 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
  • 12.4.1 FOCUS ON DEVELOPING THERAPEUTIC STRATEGIES AND INNOVATIVE APPROACHES IN DRUG DISCOVERY TO AID MARKET GROWTH

13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 US to dominate North American market during study period
  • 13.2.3 CANADA
    • 13.2.3.1 Emergence of new AI-based startups and high health expenditure to support market growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 UK
    • 13.3.2.1 Favorable government R&D funding to augment market growth
  • 13.3.3 GERMANY
    • 13.3.3.1 Presence of advanced medical infrastructure and high focus on personalized medicines to drive market
  • 13.3.4 FRANCE
    • 13.3.4.1 Strong government support and favorable strategies to propel market growth
  • 13.3.5 ITALY
    • 13.3.5.1 Advanced pharmaceutical industry and increased focus on life science R&D to fuel market growth
  • 13.3.6 SPAIN
    • 13.3.6.1 Favorable government initiatives and high investments by pharmaceutical companies to boost market growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 JAPAN
    • 13.4.2.1 High geriatric population and advanced pharmaceutical research to boost market growth
  • 13.4.3 CHINA
    • 13.4.3.1 Increasing demand for generics and rising government investments to propel market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Developed IT infrastructure and favorable government initiatives to spur market growth
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Growing biotechnology sector and increasing governmental initiatives to boost market growth
  • 13.5.3 MEXICO
    • 13.5.3.1 Favorable government initiatives and high investments by pharmaceutical companies to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure to drive market
  • 13.6.3 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
• 14.3 REVENUE ANALYSIS, 2019-2023
• 14.4 MARKET SHARE ANALYSIS, 2023
  • 14.4.1 RANKING OF KEY MARKET PLAYERS
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Use case footprint
    • 14.5.5.3 Process footprint
    • 14.5.5.4 Therapeutic area footprint
    • 14.5.5.5 Player type footprint
    • 14.5.5.6 Deployment mode footprint
    • 14.5.5.7 Region footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 14.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT AND SOLUTION LAUNCHES
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS
  • 14.9.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 NVIDIA CORPORATION
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Services/Solutions offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product and service launches
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 EXSCIENTIA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Services/Solutions offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Solution launches
      • 15.1.2.3.2 Deals
      • 15.1.2.3.3 Expansions
      • 15.1.2.3.4 Other developments
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 GOOGLE
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Services/Solutions offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Solution launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 RECURSION
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Services/Solutions offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Solution launches
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices made
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 INSILICO MEDICINE
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Services/Solutions offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product and solution launches and developments
      • 15.1.5.3.2 Deals
      • 15.1.5.3.3 Other developments
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 SCHRODINGER, INC.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Services/Solutions offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Deals
      • 15.1.6.3.2 Other developments
  • 15.1.7 BENEVOLENTAI
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Services/Solutions offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
  • 15.1.8 MICROSOFT CORPORATION
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Services/Solutions offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 ATOMWISE INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Services/Solutions offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
  • 15.1.10 ILLUMINA, INC.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Services/Solutions offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Solution launches
      • 15.1.10.3.2 Deals
  • 15.1.11 NUMEDII, INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Services/Solutions offered
  • 15.1.12 XTALPI INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products/Services/Solutions offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Deals
  • 15.1.13 IKTOS
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products/Services/Solutions offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
      • 15.1.13.3.2 Other developments
  • 15.1.14 TEMPUS
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products/Services/Solutions offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Solution launches
      • 15.1.14.3.2 Deals
      • 15.1.14.3.3 Expansions
      • 15.1.14.3.4 Other developments
  • 15.1.15 DEEP GENOMICS
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products/Services/Solutions offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Solution launches
      • 15.1.15.3.2 Deals
      • 15.1.15.3.3 Other developments
  • 15.1.16 VERGE GENOMICS
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products/Services/Solutions offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Deals
  • 15.1.17 BENCHSCI
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products/Services/Solutions offered
    • 15.1.17.3 Recent developments
      • 15.1.17.3.1 Solution launches
      • 15.1.17.3.2 Deals
      • 15.1.17.3.3 Other developments
  • 15.1.18 INSITRO
    • 15.1.18.1 Business overview
    • 15.1.18.2 Products/Services/Solutions offered
    • 15.1.18.3 Recent developments
      • 15.1.18.3.1 Deals
      • 15.1.18.3.2 Other developments
  • 15.1.19 VALO HEALTH
    • 15.1.19.1 Business overview
    • 15.1.19.2 Products/Services/Solutions offered
    • 15.1.19.3 Recent developments
      • 15.1.19.3.1 Deals
      • 15.1.19.3.2 Other developments
  • 15.1.20 BPGBIO, INC.
    • 15.1.20.1 Business overview
    • 15.1.20.2 Products/Services/Solutions offered
    • 15.1.20.3 Recent developments
      • 15.1.20.3.1 Deals
  • 15.1.21 MERCK KGAA
    • 15.1.21.1 Business overview
    • 15.1.21.2 Products/Services/Solutions offered
    • 15.1.21.3 Recent developments
      • 15.1.21.3.1 Solution launches
      • 15.1.21.3.2 Deals
      • 15.1.21.3.3 Expansions
      • 15.1.21.3.4 Other developments
• 15.2 OTHER PLAYERS
  • 15.2.1 PREDICTIVE ONCOLOGY
  • 15.2.2 IQVIA INC.
  • 15.2.3 TENCENT HOLDINGS LIMITED
  • 15.2.4 CYTOREASON LTD.
  • 15.2.5 OWKIN, INC.
  • 15.2.6 CLOUD PHARMACEUTICALS
  • 15.2.7 EVAXION BIOTECH A/S
  • 15.2.8 STANDIGM INC.
  • 15.2.9 BIOAGE LABS
  • 15.2.10 ENVISAGENICS
  • 15.2.11 ABCELLERA
  • 15.2.12 CENTELLA

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS

List of Tables

• TABLE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021-2023
• TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: FACTOR ANALYSIS
• TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: MARKET SIZING ASSUMPTIONS
• TABLE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RISK ASSESSMENT
• TABLE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS
• TABLE 7 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021-2023
• TABLE 8 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 AND 2024
• TABLE 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
• TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 NORTH AMERICA: REGULATORY FRAMEWORK
• TABLE 16 EUROPE: REGULATORY FRAMEWORK
• TABLE 17 ASIA PACIFIC: REGULATORY FRAMEWORK
• TABLE 18 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK
• TABLE 19 LATIN AMERICA: REGULATORY FRAMEWORK
• TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE SELLING PRICE, BY REGION, 2021-2023
• TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS, 2023
• TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
• TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
• TABLE 25 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
• TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: LIST OF PATENTS/PATENT APPLICATIONS
• TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
• TABLE 28 CASE STUDY 1: LEVERAGING AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE
• TABLE 29 CASE STUDY 2: ARTIFICIAL INTELLIGENCE-DRIVEN DRUG DISCOVERY AND CO-DEVELOPMENT
• TABLE 30 CASE STUDY 3: ADVANCING GENE THERAPY FOR RARE NEUROLOGICAL DISEASES
• TABLE 31 CASE STUDY 4: ARTIFICIAL INTELLIGENCE DESIGN AND OPTIMIZATION OF EXS4318
• TABLE 32 CASE STUDY 5: ARTIFICIAL INTELLIGENCE-DRIVEN DESIGN AND CLINICAL EVALUATION OF GTAEXS617
• TABLE 33 KEY ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS, BY COMPANY
• TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG REPURPOSING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 45 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY REGION, 2022-2029 (USD MILLION)
• TABLE 46 SMALL-MOLECULE DESIGN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 47 VACCINE DESIGN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 48 ANTIBODY & OTHER BIOLOGICS DESIGN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 49 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 50 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 51 SMALL-MOLECULE OPTIMIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 52 VACCINE OPTIMIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 53 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 54 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 60 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
• TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 63 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 64 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 66 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR END-TO-END SOLUTION PROVIDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 68 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR AI TECHNOLOGY PROVIDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 70 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 73 DEEP LEARNING MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 74 SUPERVISED LEARNING MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 75 REINFORCEMENT LEARNING MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 76 UNSUPERVISED LEARNING MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 77 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 78 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 79 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & COMPUTING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 80 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR COMPUTER VISION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMAGE ANALYSIS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 82 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 83 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ON-PREMISES DEPLOYMENT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 84 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CLOUD-BASED DEPLOYMENT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAAS-BASED DEPLOYMENT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 86 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 87 INDICATIVE LIST OF DEVELOPMENTS RELATED TO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
• TABLE 88 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 89 INDICATIVE LIST OF COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS
• TABLE 90 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 91 INDICATIVE LIST OF COLLABORATIONS IN RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
• TABLE 92 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 93 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 94 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 95 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022-2029 (USD MILLION)
• TABLE 96 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 97 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 98 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 99 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 100 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 101 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 102 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 103 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 104 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 105 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
• TABLE 106 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022-2029 (USD MILLION)
• TABLE 107 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 108 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 109 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 110 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 111 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 112 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 113 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 114 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 115 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 116 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022-2029 (USD MILLION)
• TABLE 117 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 118 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 119 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 120 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 121 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 122 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 123 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 124 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 125 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 126 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022-2029 (USD MILLION)
• TABLE 127 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 128 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 129 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 130 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 131 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 132 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 133 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 134 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 135 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 136 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 137 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
• TABLE 138 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 139 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 140 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 141 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 142 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 143 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 144 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 145 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 146 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 147 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 148 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 149 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 150 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 151 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 152 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 153 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 154 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 155 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 156 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 157 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 158 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 159 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 160 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 161 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 162 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 163 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 164 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 165 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 166 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 167 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 168 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 169 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 170 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 171 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 172 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 173 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 174 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 175 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 176 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 177 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 178 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 179 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 180 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 181 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 182 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 183 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 184 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 185 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 186 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 187 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 188 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 189 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 190 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 191 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 192 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 193 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 194 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 195 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 196 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 197 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 198 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022-2029 (USD MILLION)
• TABLE 199 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 200 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 201 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 202 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 203 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 204 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 205 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 206 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 207 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 208 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 209 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 210 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 211 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 212 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 213 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 214 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 215 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 216 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 217 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 218 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 219 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 220 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 221 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 222 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 223 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 224 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 225 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 226 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 227 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 228 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 229 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 230 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 231 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 232 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 233 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 234 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 235 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 236 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 237 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 238 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 239 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 240 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 241 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 242 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 243 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 244 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 245 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 246 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 247 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 248 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 249 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 250 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 251 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 252 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 253 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 254 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 255 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 256 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 257 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 258 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 259 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 260 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 261 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 262 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 263 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 264 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 265 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 266 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 267 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 268 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 269 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 270 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 271 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 272 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 273 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 274 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 275 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 276 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 277 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 278 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 279 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 280 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022-2029 (USD MILLION)
• TABLE 281 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 282 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 283 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 284 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 285 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022-2029 (USD MILLION)
• TABLE 286 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022-2029 (USD MILLION)
• TABLE 287 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 288 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022-2029 (USD MILLION)
• TABLE 289 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022-2029 (USD MILLION)

List of Figures

• FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SEGMENTS AND REGIONS CONSIDERED
• FIGURE 2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: YEARS CONSIDERED
• FIGURE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RESEARCH DESIGN
• FIGURE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY DATA FROM SECONDARY SOURCES
• FIGURE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY PRIMARY SOURCES
• FIGURE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY DATA FROM PRIMARY SOURCES
• FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY INDUSTRY INSIGHTS
• FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
• FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• FIGURE 10 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
• FIGURE 12 BOTTOM-UP APPROACH: END-USER SPENDING ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
• FIGURE 13 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
• FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TOP-DOWN APPROACH
• FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DATA TRIANGULATION
• FIGURE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2024 VS. 2029 (USD MILLION)
• FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION)
• FIGURE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024 VS. 2029 (USD MILLION)
• FIGURE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024 VS. 2029 (USD MILLION)
• FIGURE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL SNAPSHOT
• FIGURE 25 INCREASING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS TO DRIVE MARKET
• FIGURE 26 US AND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2023
• FIGURE 27 INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029
• FIGURE 28 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 29 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
• FIGURE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 31 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003-2023
• FIGURE 32 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015-2023
• FIGURE 33 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• FIGURE 34 EVOLUTION OF AI IN DRUG DISCOVERY MARKET
• FIGURE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: STRUCTURE-BASED DRUG DESIGNING
• FIGURE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS
• FIGURE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TYPES OF SERVICE
• FIGURE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
• FIGURE 41 KEY BUYING CRITERIA FOR TOP THREE END USERS
• FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR "AI IN DRUG DISCOVERY" PATENTS (JANUARY 2015-SEPTEMBER 2024)
• FIGURE 43 MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (JANUARY 2015-SEPTEMBER 2024)
• FIGURE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BUSINESS MODELS
• FIGURE 45 BENEFITS OF HYBRID BUSINESS MODELS
• FIGURE 46 SPECIALIZATION OF ARTIFICIAL INTELLIGENCE-BASED COMPANIES OVER TIME
• FIGURE 47 FUNDING IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, 2013-2022 (USD MILLION)
• FIGURE 48 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING LABORATORY INFORMATICS ACROSS INDUSTRIES
• FIGURE 49 IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
• FIGURE 50 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2023
• FIGURE 51 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
• FIGURE 52 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023)
• FIGURE 53 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
• FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2019-2023)
• FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2023)
• FIGURE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RANKING OF KEY MARKET PLAYERS (2023)
• FIGURE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT
• FIGURE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 60 EV/EBITDA OF KEY VENDORS
• FIGURE 61 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 63 NVIDIA CORPORATION: COMPANY SNAPSHOT
• FIGURE 64 EXSCIENTIA: COMPANY SNAPSHOT
• FIGURE 65 GOOGLE: COMPANY SNAPSHOT
• FIGURE 66 RECURSION: COMPANY SNAPSHOT
• FIGURE 67 SCHRODINGER, INC.: COMPANY SNAPSHOT
• FIGURE 68 BENEVOLENTAI: COMPANY SNAPSHOT
• FIGURE 69 MICROSOFT CORPORATION: COMPANY SNAPSHOT
• FIGURE 70 ILLUMINA, INC.: COMPANY SNAPSHOT
• FIGURE 71 MERCK KGAA: COMPANY SNAPSHOT